Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| NovaBay Pharmaceuticals Inc New | NBY | AMEX | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.0% | 0.597 | 0.00 | 0.00 | 0.00 | 0.597 | 07:34:07 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 0.00 | USD |
NovaBay Pharmaceuticals Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 15.05M | 25.20M | $ -6.55M | -0.46 | - | 23.30M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| 663.02k | $ - | 0.00% | -4.00 | 7.50% |
NovaBay Pharmaceuticals News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NBY Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol [m] | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.61 | 0.6672 | 0.54 | 0.6171 | 180k | -0.013 | -2.13% |
| 1 Month | 0.8 | 0.84 | 0.51 | 0.6336 | 496k | -0.203 | -25.38% |
| 3 Months | 1.22 | 1.42 | 0.421 | 0.6697 | 924k | -0.623 | -51.07% |
| 6 Months | 1.1 | 4.78 | 0.229 | 1.8742 | 2M | -0.503 | -45.73% |
| 1 Year | 1.56 | 4.78 | 0.229 | 1.8681 | 946k | -0.963 | -61.73% |
| 3 Years | 3.9499 | 5.0851 | 0.229 | 1.9181 | 327k | -3.3529 | -84.89% |
| 5 Years | 19.25 | 26.25 | 0.229 | 4.7690 | 276k | -18.653 | -96.90% |
NovaBay Pharmaceuticals Description
| NovaBay Pharmaceuticals Inc is a biopharmaceutical company. The company develops, manufactures, and markets anti-infective products for a multitude of uses. It is predominantly focused on commercializing prescription Avenova for the domestic eyecare market in the United States. Avenova is the only eye care product formulated with proprietary, stable and pure form of hypochlorous acid (marketed as Neutrox). NovaBay develops additional products containing Neutrox, including its NeutroPhase Skin and Wound Cleanser for wound care and CelleRx for the dermatology market. It has partnerships for NeutroPhase in the United States, as well as in other markets. |
